A New Approach to the Quantification of Fibroblast Growth Factor 23-An Array Surface Plasmon Resonance Imaging Biosensor

A new biosensor based on the surface plasmon resonance imaging (SPRi) detection technique for the quantification of fibroblast growth factor 23 (FGF23) has been developed. FGF23 is mainly produced in bone tissues as a phosphaturic hormone that forms a trimeric complex with fibroblast growth factor receptor 1 (FGFR1) and alpha Klotho upon secretion. FGF23 stimulates phosphate excretion and inhibits the formation of active vitamin D in the kidneys. FGF23 has been shown to play a role in bone carcinogenesis and metastasis. The newly developed method, based on the array SPRi biosensor, was validated-the precision, accuracy, and selectivity were acceptable, and yielded less than +/- 10% recovery. The rectilinear response of the biosensor ranges from 1 to 75 pg/mL. The limit of detection was 0.033 pg/mL, and the limit of quantification was 0.107 pg/mL. The biosensor was used to determine FGF23 concentrations in the blood plasma of healthy subjects and patients with clear cell renal cell carcinoma (ccRCC). The obtained results were compared with those measured through an enzyme-linked immunosorbent assay (ELISA). The determined Pearson correlation coefficients were 0.994 and 0.989, demonstrating that the newly developed biosensor can be used as a competitive method for the ELISA.

Automated summary

A new biosensor based on surface plasmon resonance imaging (SPRi) detection technique has been developed for quantifying fibroblast growth factor 23 (FGF23). The biosensor showed acceptable precision, accuracy, and selectivity, with a wide linear response range and low limits of detection and quantification.